Brinzolamide + Brimonidine TartrateThird Party Manufacturing in India

Brinzolamide + Brimonidine Tartrate works through a complementary mechanism where brinzolamide inhibits carbonic anhydrase II to decrease bicarbonate ion secretion and aqueous fluid production, while brimonidine reduces fluid production and enhances uveoscleral outflow. They act on these targets to help the body achieve significant reductions in elevated intraocular pressure. Unlike mono-therapies, this combination provides a superior synergistic effect without exposing the patient to increased systemic risks. It is highly effective and well-tolerated.

Therapeutic Uses

• Advanced Glaucoma: Indicated for the reduction of intraocular pressure in adult patients with open-angle glaucoma where monotherapy provides insufficient control.
• Severe Ocular Hypertension: Formulated for rapid and sustainable management of high intraocular fluid pressure.

Why Manufacturers Choose Brinzolamide + Brimonidine Tartrate

Brinzolamide + Brimonidine Tartrate third party manufacturing in India is a highly valued niche because it targets advanced clinical cases where combination therapy is essential for vision preservation. Celesta coordinates the production using state-of-the-art partner facilities that are WHO-GMP certified, utilizing complex suspension-stabilizing technologies to avoid active ingredient precipitation. This premium medical formulation helps brands stand out in competitive ophthalmic markets under certified WHO-GMP manufacturing agreements.